Cardiac Assist Devices Are Mechanical Pumps That Are Implanted In Patients Having Acute Heart Failure For Enhancing The Pumping Efficiency And Maintaining Optimal Blood Flow In The Body

 

Cardiac Assist Devices

Cardiac Assist Devices are used in patients with severe heart failure, acute mitral valve regurgitation, and unstable angina. The first LVADs were pulsatile pumps. Due to large number of components that could fail, these devices were associated with a number of complications. Since the first devices, improvements have been made in their efficiency and implantability.

According to Coherent Market Insights the Cardiac Assist Devices Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028.

Cardiovascular diseases (CVDs) are a major cause of morbidity and mortality in the United States and contribute to an estimated total cost of $1.1 trillion by 2035. A rise in the number of CVD cases is also expected to contribute to a growing number of research and development activities.

Various cardiovascular devices have been developed to help patients with cardiovascular diseases. They are made from a variety of biomaterials, including synthetic polymers, metallic alloys, and biologic tissues. The resulting devices help restore the physiological properties of the human body. However, they also carry a variety of risks. Biomaterial-associated infection is one of the most common complications.

Ventricular assist devices (VADs) are devices that provide support for the left ventricle. These devices can be placed externally or internally. They can also be placed in the abdominal cavity or the thoracic cavity. The devices are made up of inflow and outflow cannulae, connectors, and controllers. The devices are designed to palliate severe congestive heart failure. They have been used in the treatment of cardiogenic shock, end-stage heart failure, and intraoperative cardiac procedures.

VADs can be used to help make decisions, restore circulation to organs, and bridge patients to more definitive devices. These devices can be used as destination therapy or as a bridge to transplant therapy.

Ventricular assist devices can be placed externally or internally. The device is made up of inflow and outflow cannulae, and the pump uses pulsatile air pressure to deliver blood to the ventricle's pneumatic chamber. The pump uses a piston-type driver to generate the pulsatile air pressure. The device is synchronized with the arterial pressure curve to ensure that the patient's heart is receiving sufficient blood flow. In order to ensure proper functioning, a multidisciplinary team is necessary.

SynCardia Systems LLC, received approval from the US Food and Drug Administration for their 50CC temporary total artificial heart system in March 2020. This system acts as a bridge during heart transplant of patients at the risk of death due to biventricular failure.